Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $33.89
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.61M
Market Cap
$14.57B
Enterprise Value$15.46B
Total Cash (Recent Filing)$35.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.42
Next Earnings
May 08, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding737,679,700
10 Day Avg. Volume2,483,455
30 Day Avg. Volume2,613,706
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-74.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.03K
Enterprise Value/Ebitda-83.67
Forecast
1Y Price Target
$35.57Price Target Upside71.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentIvonescimab's traits are enabling activity beyond what is expected from an antibody combo, indicating ample room for upside.
Earnings PotentialIf ivonescimab continues to show robust efficacy and favorable safety broadly in oncology, it could potentially achieve peak annual sales far exceeding the $25 billion notched by KEYTRUDA.
Market PotentialIvonescimab’s potential market is far broader than lung cancers, tapping into a significant portion of Keytruda's sales.
Bears Say
Clinical Trial ResultsNo additional information was provided on the timing of the HARMONi-2 overall survival data.
Clinical TrialsSome investors are concerned about whether ivonescimab can beat the overall survival hazard ratio in the MARIPOSA-2 trial.
Investor SentimentInvestor concerns exist regarding whether ivonescimab can beat the overall survival hazard ratio in the MARIPOSA-2 trial of RYBREVANT.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $2.10 and its highest was $33.89 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $14.57B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Feb 24, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.002.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 737,679,700 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went down -14.828%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
---
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.57 (71.92% Upside)
$35.57 (71.92% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 11.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
456.33%
12-Months-Change
Fundamentals
Return on Equity
-94.89%
Trailing 12-Months
Asset Growth
114.62%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibiotics to combat infections caused by multi-drug resistant bacteria. The company operates in the healthcare sector, with a primary focus on developing new treatments for infectious diseases through its innovative pipeline of antibiotic candidates.
---
SMMT Company Deck
---
SMMT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Summit Therapeutics, marked by significant collaborations, financial stability, and progress in clinical trials. However, some uncertainties around trial timelines and reliance on partnerships were noted.Read More>---
SMMT Stock 12 Month Forecast
Average Price Target
$35.57
▲(71.92% Upside)
Technical Analysis
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+205.46%
reiterated a buy rating 15 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +205.46% per trade.
---